BMS Event: Retinoblastoma Diagnostics
The Glycobiology Group of the MPI-KG BMS (Prof. Peter H. Seeberger, Dr. Chakkumkal Anish, Mr. Geißner), Kinderkrebsstiftung (Dr. Gregor König), sphingotec GmbH (Dr. Andreas Bergmann) and University Klinikum Essen (Dr. Petra Temming and Prof. Johannes Schulte) joined their expertise to identify novel glycan-based tumor markers or tumour associated carbohydrate antigens (TACA) for potential diagnosis and prognosis of the retinoblastoma disease. ...
During the year-long study, a set of dozen new TACAs was synthesized and characterized, followed by glycan array construction and immune assay development and validation. In a follow-up study, scientists of the glycobiology group will screen higher number of relevant samples provided by the University Klinikum Essen. This will enable statistical and practical interpretation of the study, as well as its possible expansion into diagnostics of other cancers.
Retinoblastoma is a rapidly developing cancer in children that develops form immature cells of the retina. Most children are diagnosed early and the overall survival rate exceeds 95%. However, the prognosis of metastasized retinoblastoma remains poor. In 40% of the patients, retinoblastoma occurs bilaterally and, especially for these children, the salvage of the eye and visual function is of major importance. Genetic testing helps to identify the children with heritable (50% of patients) retinoblastoma. These children have a genetic predisposition for second malignancies. For this reason, late effects are an increasing concern and the care of patients with retinoblastoma requires a multidisciplinary approach to tailor therapy and long-term follow-up. Identifying novel biomarkers that can support prognosis of metastasized retinoblastoma is very important. In Germany, about 40 children per year are affected by the disease.